The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2024 | COMPASSION-15: cadonilimab in advanced gastric cancers
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents the results of the randomized, double-blind, Phase III COMPASSION-15 trial (NCT05008783). The study showed that administering cadonilimab, an anti-PD-L1 and CTLA-4 bispecific antibody, resulted in a promising response rate in patients with unresectable locally advanced or metastatic gastric cancer. These findings suggest that the dual PD-L1 and CTLA4 blockade can be targeted safely in combination with chemotherapy. Dr Janjigian concludes that a follow-up and efficacy study is required in the Western patient populace, with a comparator cohort other than chemotherapy, such as nivolumab. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
